JOURNAL OF VIROLOGY

Limit the abstract to 250 words or fewer and concisely summarize the basic content of the paper without presenting extensive experimental details. Avoid abbreviations and references, and do not include diagrams. When it is essential to include a reference, use the same format as shown for the References section but omit the article title. Because the abstract will be published separately by abstracting services, it must be complete and understandable without reference to the text. Authors should indicate the specific virus(es) under study in the title or abstract as appropriate. Introduction. The introduction should supply sufficient background information to allow the reader to understand and evaluate the results of the present study without referring to previous publications on the topic. The introduction should also provide the hypothesis that was addressed or the rationale for the present study. Choose references carefully to provide the most salient background rather than an exhaustive review of the topic. Materials and Methods. The Materials and Methods section should include sufficient technical information to allow the experiments to be repeated. When centrifugation conditions are critical, give enough information to enable another investigator to repeat the procedure: make of centrifuge, model of rotor, temperature, time at maximum speed, and centrifugal force ( g rather than revolutions per minute). For commonly used materials and methods (e.g., media and protein concentration determinations), a simple reference is sufficient. If several alternative methods are commonly used, it is helpful to identify the method briefly as well as to cite the reference. For example, it is preferable to state “cells were broken by ultrasonic treatment as previously described (9)” rather than to state “cells were broken as previously described (9).” This allows the reader to assess the method without constant reference to previous publications. Describe new methods completely and give sources of unusual chemicals, equipment, or microbial strains. When large numbers of microbial strains or mutants are used in a study, include tables identifying the immediate sources (i.e., sources from whom the strains were obtained) and properties of the strains, mutants, bacteriophages, and plasmids, etc. A method or strain, etc., used in only one of several experiments reported in the paper may be described in the Results section or very briefly (one or two sentences) in a table footnote or figure legend. It is expected that the sources from whom the strains were obtained will be identified. Results. In the Results section, include the rationale or design of the experiments as well as the results; reserve extensive interpretation of the results for the Discussion section. Present the results as concisely as possible in one of the following: text, table(s), or figure(s). Data in tables (e.g., cpm of radioactivity) should not contain more significant figures than the precision of the measurement allows. Illustrations (particularly photomicrographs and electron micrographs) should be limited to those that are absolutely necessary to show the experimental findings. Number figures and tables in the order in which they are cited in the text, and be sure to cite all figures and tables. Discussion. The Discussion should provide an interpretation of the results in relation to previously published work and to the experimental system at hand and should not contain extensive repetition of the Results section or reiteration of the introduction. In short papers, the Results and Discussion sections may be combined. Acknowledgments. The source of any financial support received for the work being published must be indicated in the Acknowledgments section. (It will be assumed that the absence of such an acknowledgment is a statement by the authors that no support was received.) The usual format is as follows: “This work was supported 1

[1]  H. Lane,et al.  Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins , 1997, The Journal of experimental medicine.

[2]  Erik Hooijberg,et al.  Immortalization of Human CD8+ T Cell Clones by Ectopic Expression of Telomerase Reverse Transcriptase1 , 2000, The Journal of Immunology.

[3]  R. Effros,et al.  Mechanism of telomerase induction during T cell activation. , 1996, Experimental cell research.

[4]  T. Braciale,et al.  Why can't cytotoxic T cells handle HIV? , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[6]  D. Engelman,et al.  Polar residues drive association of polyleucine transmembrane helices , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Young,et al.  Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 , 1994, The Journal of experimental medicine.

[8]  N. Rufer,et al.  Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. , 2001, Blood.

[9]  P. Romero,et al.  Ectopic Human Telomerase Catalytic Subunit Expression Maintains Telomere Length But Is Not Sufficient for CD8+ T Lymphocyte Immortalization1 , 2000, The Journal of Immunology.

[10]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[11]  C. Harley,et al.  Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. , 1996, AIDS.

[12]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[13]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[14]  David S Schneider,et al.  Screening the fruitfly immune system , 2002, Genome Biology.

[15]  M. Gill,et al.  Accelerated replicative senescence of the peripheral immune system induced by HIV infection , 2000, AIDS.

[16]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[17]  J. Lieberman,et al.  Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. , 2001, Blood.

[18]  B. Walker,et al.  β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans , 1998, Nature.

[19]  B. Walker,et al.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens , 1993, Journal of virology.

[20]  G. Pawelec,et al.  Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? , 1997, Immunology today.

[21]  C. Greider,et al.  Telomerase regulation during entry into the cell cycle in normal human T cells. , 1996, Molecular biology of the cell.

[22]  R. Young,et al.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Phillips,et al.  Escape of human immunodeficiency virus from immune control. , 1997, Annual review of immunology.

[24]  Nam W. Kim,et al.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP) , 1997, Nucleic Acids Res..

[25]  Andrea Bodnar,et al.  Human Endothelial Cell Life Extension by Telomerase Expression* , 1999, The Journal of Biological Chemistry.

[26]  S. Benchimol,et al.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span , 1998, Current Biology.

[27]  B. Walker,et al.  Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Buseyne,et al.  Dual function of a human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte clone: inhibition of HIV replication by noncytolytic mechanisms and lysis of HIV-infected CD4+ cells. , 1996, Virology.

[29]  R P Johnson,et al.  Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes , 1996, Journal of virology.

[30]  E. Topp,et al.  Effect of Subtherapeutic Administration of Antibiotics on the Prevalence of Antibiotic-Resistant Escherichia coli Bacteria in Feedlot Cattle , 2008, Applied and Environmental Microbiology.

[31]  B. Levine,et al.  Regulated expression of telomerase activity in human T lymphocyte development and activation , 1996, The Journal of experimental medicine.

[32]  B. Walker,et al.  CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. , 1997, Advances in immunology.

[33]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[34]  J. Shay,et al.  Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. , 1995, Journal of immunology.

[35]  R P Johnson,et al.  Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms , 1997, Journal of virology.

[36]  C B Harley,et al.  Telomere length predicts replicative capacity of human fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Campisi From cells to organisms: can we learn about aging from cells in culture? , 2001, Experimental Gerontology.

[38]  R. Colvin,et al.  Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. , 1987, Journal of immunology.

[39]  Michael Forman,et al.  Specimen Collection, Transport, and Processing: Virology , 2011 .

[40]  V A Zakian,et al.  Structure and function of telomeres. , 1989, Annual review of genetics.

[41]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[42]  M. Falagas,et al.  Use of International Units When Dosing Colistin Will Help Decrease Confusion Related to Various Formulations of the Drug around the World , 2006, Antimicrobial Agents and Chemotherapy.

[43]  C. Hallahan,et al.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors , 2002, Nature Immunology.

[44]  Douglas D. Richman,et al.  HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function , 2000, The Journal of experimental medicine.

[45]  David Toll,et al.  How Do You Improve Compliance? , 2005, Pediatrics.

[46]  Niels Schaft,et al.  T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover , 1996, Science.